A spatially repellent product could reduce dengue and Zika infections by about 34 percent. This is evident from new research published by the University of Notre Dame in collaboration with the University of California, Davis, and US Naval Medical Research Unit Six.
The data comes from a Peruvian study and is the second clinical study in a 5-year program to investigate the effects of spatial repellants on reducing mosquito-borne disease.
On October 27, 2020, Nicole L. Achee, co-principal investigator of the study and research professor at the Department of Biological Sciences in Notre Dame, said in a press release: “This is the first clinical study that shows a spatial closure can repellent in humans Aedes-borne viral infection – a milestone in the research and development of spatial repellants as an effective intervention in disease control programs. “
“This result helps provide evidence that spatial repellants have the potential to improve public health in areas of the world where mosquito-borne diseases are a significant burden.”
In addition to reducing Aedes-borne virus infection rates by an estimated 34%, the researchers found that SC Johnson’s first generation spatial defense technology significantly reduced the number of mosquitoes found indoors by about 29%.
“As part of our commitment to address some of the most pressing public health threats in the world, SC Johnson is proud to support efforts to prevent disease and create opportunities for better quality of life for underserved populations,” added Fisk Johnson, Ph. D., added. , Chairman and CEO of SC Johnson.
“Life-threatening diseases like dengue and zika are preventable, but billions of people around the world do not have access to personal protection methods. We are working to prove the effectiveness of this spatial repellent so we can get it into public health systems and save lives. “
While progress has been made in lowering death rates, the World Health Organization (WHO) has reported that Zika cases have decreased worldwide. However, this remains a challenging disease for vulnerable communities in endemic areas. As a result, families need additional tools to protect themselves from mosquitoes and the diseases they may be carrying.
Spatial repellants offer a new way for public health organizations to fill the supply gap in mosquito bite prevention, according to the WHO.
Thomas Mascari, Ph.D., Entomologist at SC Johnson commented, “This study is the most robust and conclusive study yet to demonstrate the protection of an insecticidal product against Aedes-borne viruses and that spatial repellants can have a beneficial effect the practice in reducing the transmission of these diseases. “
SC Johnson provided integral industry and product expertise, manufacturing and market access, particularly in the development and manufacture of the Mosquito Shield ™ products used in Notre Dame University clinical trials.
Transfluthrin, the active ingredient in Mosquito Shield ™, is released passively using a natural flow of air to protect people in a specific area from mosquitos. This active ingredient is registered with the U.S. Environmental Protection Agency and is used in pest control products around the world.
An optimized version of the Mosquito Shield, which will air for 30 days, will be used in upcoming large-scale clinical trials funded by UNITAID in Mali, Kenya and Sri Lanka.
For more information on SC Johnson and its corporate social responsibility efforts, please visit SC Johnson.
ZikaNews publishes research-based news.